drugset / Trial / NCT05373355

Safety and Efficacy of TLL018 in Patients With Chronic Spontaneous Urticaria.

NCT05373355

Phase 1 Completed 41 enrolled Hangzhou Highlightll Pharmaceutical Co., Ltd
RandomizedParallel-groupDouble-blindOther

Summary

This study is a randomized, double-blind, placebo-controlled, multicenter clinical trial of about 36 subjects with moderate to severe Chronic Spontaneous Urticaria.

Timeline

Start
2022-05-10
Primary completion
2023-09-07
Completion
2023-09-07

Drugs

EvaluationDrugModalityDoseRoute
Subject TLL018 Unknown 1 unknown Oral
Subject TLL018 Unknown 3 unknown Oral